09:08 AM EDT, 10/13/2025 (MT Newswires) -- Immutep ( IMMP ) said Monday it received "positive and straightforward" feedback from the US Food and Drug Administration regarding successful completion of Project Optimus dosing requirements and agreement on 30 milligrams as the best dosage for its cancer immunotherapy eftilagimod alfa.

The agreement will help in future clinical development of the therapy, including an ongoing phase 3 trial evaluating it in combination with Merck's (MRK) Keytruda and chemotherapy as first-line treatment for advanced or metastatic non-small cell lung cancer, the company said.

With the conclusion of the dosing optimization, the trial is now opening test sites in the US, the company said.

Shares of Immutep ( IMMP ) were up 3.9% in recent premarket activity.